{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:22:29Z","timestamp":1788844949240,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001343","name":"University of Pretoria","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001343","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Limited knowledge is available on the incidence of febrile neutropenia (FN) in intermediate-risk patients and the rationale for use of granulocyte colony-stimulating factor (G-CSF) in these patients. We aimed to estimate the rate at which patients associated with intermediate risk (10\u201320%) of FN would develop\u2009\u2265\u20091 episode of FN with a commonly used chemotherapy regimen in clinical practice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This prospective, real-world, observational, multinational, multicenter study (December 2016\u2013October 2019) recruited patients with solid tumors or Hodgkin\u2019s\/non-Hodgkin\u2019s lymphoma. Patients receiving chemotherapy with intermediate risk of FN, but not G-CSF as primary prophylaxis were included and observed for the duration of the chemotherapy (\u2264\u20096 cycles and\u2009\u2264\u200930\u00a0days after the last chemotherapy administration).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 364 patients (median age, 56\u00a0years) with 1601 cycles of chemotherapy were included in the analysis. The incidence of FN was 5% in cycle 1, 3% in cycles 2\u20133, and 1% in cycles 4\u20136. The rate of patients with\u2009\u2265\u20091 episode of FN was 9%, and 59% of FN events were reported during cycle 1. The rate of grade 4 neutropenia in cycle 1 was 11%, and 15% of patients experienced\u2009\u2265\u20091 episode of grade 4 neutropenia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Overall, the incidence of FN was low, with a high incidence in cycle 1 and a decrease in the subsequent cycles. These results provide the real FN risk for common chemotherapy regimens in patients generally excluded from clinical trials. Prophylactic G-CSF in intermediate-risk patients could be considered as per clinician\u2019s judgement.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-023-08071-0","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T01:02:12Z","timestamp":1697158932000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiative"],"prefix":"10.1007","volume":"31","author":[{"given":"Bernardo","family":"Leon Rapoport","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcial","family":"Garcia-Morillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carme","family":"Font","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zarka","family":"Samoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan Abdul","family":"Jabbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hampig Raphael","family":"Kourie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Kayumba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razvan Andrei","family":"Popescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Garc\u00eda-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liezl","family":"Heyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andriy","family":"Krendyukov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Mathieson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Cooksley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Klastersky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,13]]},"reference":[{"issue":"4","key":"8071_CR1","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/0300891620927093","volume":"106","author":"AC Tralongo","year":"2020","unstructured":"Tralongo AC, Antonuzzo A, Pronzato P, Sbrana A, Turrini M, Zoratto F, Danova M (2020) Management of chemotherapy-induced neutropenia in patients with cancer: 2019 guidelines of the Italian Medical Oncology Association (AIOM). Tumori Journal 106(4):273\u2013280","journal-title":"Tumori Journal"},{"key":"8071_CR2","doi-asserted-by":"publisher","unstructured":"Kuderer NM, Desai A, Lustberg MB, Lyman GH (2022) Mitigating acute chemotherapy-associated adverse events in patients with cancer. Nat Rev Clin Oncol\u00a019(11):681-697.\u00a0https:\/\/doi.org\/10.1038\/s41571-022-00685-3","DOI":"10.1038\/s41571-022-00685-3"},{"key":"8071_CR3","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky J, De Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, Herrstedt J (2016) Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol 27:v111\u2013v118","journal-title":"Ann Oncol"},{"issue":"7","key":"8071_CR4","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s40265-018-0909-3","volume":"78","author":"PM Kasi","year":"2018","unstructured":"Kasi PM, Grothey A (2018) Chemotherapy-induced neutropenia as a prognostic and predictive marker of outcomes in solid-tumor patients. Drugs 78(7):737\u2013745","journal-title":"Drugs"},{"issue":"2","key":"8071_CR5","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s00520-020-05906-y","volume":"29","author":"T Cooksley","year":"2021","unstructured":"Cooksley T, Font C, Scotte F, Escalante C, Johnson L, Anderson R, Rapoport B (2021) Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of COVID-19: a MASCC position paper. Support Care Cancer 29(2):1129\u20131138","journal-title":"Support Care Cancer"},{"key":"8071_CR6","unstructured":"BL R Febrile Neutropenia - Guideline Update and Approach to Management of Both High and Intermediate-Risk Patients. https:\/\/mascc.org\/wp-content\/uploads\/2022\/04\/1114_Rapoport_Strauss-1-2_Sat.pdf. Accessed November 23 2022"},{"key":"8071_CR7","unstructured":"NCCN Clinical Practice Guidelines in Oncology (2022) Prevention and Treatment of Cancer-Related Infections, version 1. 2022. National Cancer Comprehensive Network website. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/infections.pdf. Accessed November 23 2022"},{"issue":"1","key":"8071_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JOP.2014.001492","volume":"11","author":"D Weycker","year":"2015","unstructured":"Weycker D, Li X, Edelsberg J, Barron R, Kartashov A, Xu H, Lyman GH (2015) Risk and consequences of chemotherapy-induced febrile neutropenia in patients with metastatic solid tumors. J Oncol Pract 11(1):47\u201354","journal-title":"J Oncol Pract"},{"key":"8071_CR9","doi-asserted-by":"publisher","unstructured":"Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25(21):3158\u201367.\u00a0https:\/\/doi.org\/10.1200\/JCO.2006.08.8823","DOI":"10.1200\/JCO.2006.08.8823"},{"issue":"1","key":"8071_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"M Aapro","year":"2011","unstructured":"Aapro M, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman G, Pettengell R, Tjan-Heijnen V, Walewski J (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8\u201332","journal-title":"Eur J Cancer"},{"issue":"4","key":"8071_CR11","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young J-AH, Wingard JR (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52(4):e56\u2013e93","journal-title":"Clin Infect Dis"},{"issue":"28","key":"8071_CR12","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 33(28):3199\u20133212","journal-title":"J Clin Oncol"},{"key":"8071_CR13","doi-asserted-by":"crossref","unstructured":"Rapoport BL, Aapro M, Paesmans M, Van Eeden R, Smit T, Krendyukov A, Klastersky J (2018) Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinational study. BMC Cancer 18 (1):1\u20138","DOI":"10.1186\/s12885-018-4838-z"},{"issue":"9","key":"8071_CR14","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.6004\/jnccn.2017.7010","volume":"15","author":"Y Li","year":"2017","unstructured":"Li Y, Family L, Yang S-J, Klippel Z, Page JH, Chao C (2017) Risk of febrile neutropenia associated with select myelosuppressive chemotherapy regimens in a large community-based oncology practice. J Natl Compr Canc Netw 15(9):1122\u20131130","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"8071_CR15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373\u2013383","journal-title":"J Chronic Dis"},{"issue":"6","key":"8071_CR16","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, Januel J-M, Sundararajan V (2011) Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173(6):676\u2013682","journal-title":"Am J Epidemiol"},{"issue":"4","key":"8071_CR17","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/annonc\/mdv619","volume":"27","author":"J Truong","year":"2016","unstructured":"Truong J, Lee EK, Trudeau ME, Chan KK (2016) Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis. Ann Oncol 27(4):608\u2013618. https:\/\/doi.org\/10.1093\/annonc\/mdv619","journal-title":"Ann Oncol"},{"issue":"7","key":"8071_CR18","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.annonc.2020.04.005","volume":"31","author":"M Clemons","year":"2020","unstructured":"Clemons M, Fergusson D, Simos D, Mates M, Robinson A, Califaretti N, Zibdawi L, Bahl M, Raphael J, Ibrahim MFK, Fernandes R, Pitre L, Aseyev O, Stober C, Vandermeer L, Saunders D, Hutton B, Mallick R, Pond GR, Awan A, Hilton J (2020) A multicentre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer. Ann Oncol 31(7):951\u2013957. https:\/\/doi.org\/10.1016\/j.annonc.2020.04.005","journal-title":"Ann Oncol"},{"issue":"1","key":"8071_CR19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4103\/sajc.sajc_439_18","volume":"9","author":"NR Palukuri","year":"2020","unstructured":"Palukuri NR, Yedla RP, Bala SC, Kuruva SP, Chennamaneni R, Konatam ML, Gundeti S (2020) Incidence of febrile neutropenia with commonly used chemotherapy regimen in localized breast cancer. South Asian J Cancer 9(1):4\u20136. https:\/\/doi.org\/10.4103\/sajc.sajc_439_18","journal-title":"South Asian J Cancer"},{"issue":"2","key":"8071_CR20","doi-asserted-by":"publisher","first-page":"249","DOI":"10.4103\/ijmpo.ijmpo_31_18","volume":"40","author":"MLSN Philip","year":"2019","unstructured":"Philip MLSN, Sebastian MA, Mateti UV et al (2019) Assessment of chemotherapy-induced febrile neutropenia in cancer patients. IJMPO 40(2):249\u2013256. https:\/\/doi.org\/10.4103\/ijmpo.ijmpo_31_18","journal-title":"IJMPO"},{"key":"8071_CR21","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1186\/s40064-015-1165-6","volume":"4","author":"E Culakova","year":"2015","unstructured":"Culakova E, Poniewierski MS, Wolff DA, Dale DC, Crawford J, Lyman GH (2015) The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort study. Springerplus 4:396. https:\/\/doi.org\/10.1186\/s40064-015-1165-6","journal-title":"Springerplus"},{"issue":"3","key":"8071_CR22","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00520-010-0821-1","volume":"19","author":"W Hosmer","year":"2011","unstructured":"Hosmer W, Malin J, Wong M (2011) Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer. Support Care Cancer 19(3):333\u2013341. https:\/\/doi.org\/10.1007\/s00520-010-0821-1","journal-title":"Support Care Cancer"},{"key":"8071_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.697908","volume":"11","author":"GH Lyman","year":"2021","unstructured":"Lyman GH, Kuderer NM, Aapro M (2021) Improving outcomes of chemotherapy: established and novel options for myeloprotection in the COVID-19 era. Front Oncol 11:697908. https:\/\/doi.org\/10.3389\/fonc.2021.697908","journal-title":"Front Oncol"},{"issue":"9","key":"8071_CR24","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1007\/s00520-017-3692-x","volume":"25","author":"AA Kawatkar","year":"2017","unstructured":"Kawatkar AA, Farias AJ, Chao C, Chen W, Barron R, Vogl FD, Chandler DB (2017) Hospitalizations, outcomes, and management costs of febrile neutropenia in patients from a managed care population. Support Care Cancer 25(9):2787\u20132795. https:\/\/doi.org\/10.1007\/s00520-017-3692-x","journal-title":"Support Care Cancer"},{"key":"8071_CR25","unstructured":"European Society for Medical Oncology (2020) Supportive Care Strategies During the COVID-19 Pandemic. https:\/\/www.esmo.org\/guidelines\/cancer-patient-management-during-the-covid-19-pandemic\/supportivecare-in-the-covid-19-era. Accessed November 23 2022"},{"key":"8071_CR26","doi-asserted-by":"publisher","unstructured":"Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P, Geyer MB, Gojo I, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Lyman GH, Mukherjee S, Perez LE, Rosovsky RP, Roy V, Rugo HS, Vasu S, Wadleigh M, Westervelt P, Becker PS (2020) Considerations for use of hematopoietic growth factors in patients with cancer related to the COVID-19 pandemic. J Natl Compr Canc Netw 1\u20134. https:\/\/doi.org\/10.6004\/jnccn.2020.7610","DOI":"10.6004\/jnccn.2020.7610"},{"key":"8071_CR27","unstructured":"American Society of Clinical Oncology (2020) COVID-19 Patient Care Information. Cancer Treatment & Supportive Care. https:\/\/www.asco.org\/asco-coronavirus-resources\/care-individuals-cancer-during-covid-19\/cancer-treatment-supportive-care. Accessed November 23 2022"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-08071-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-08071-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-08071-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T10:05:55Z","timestamp":1702548355000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-08071-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["8071"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-08071-0","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,13]]},"assertion":[{"value":"24 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. The study protocol and all amendments were reviewed by the independent ethics committee or institutional review board for each center. The ethics approval was obtained from the Ethics Review Committee of The Aga Khan University (Pakistan; Reference number: 2019\u20130827-2451), Hotel-Dieu de France Ethics Committee of the Universit\u00e9 Saint-Joseph de Beyrouth (Lebanon; Reference number: CEHDF 1038), Ethics Committee Northwest and Central Switzerland (EKNZ, Switzerland; Reference number: 2018\u201301603), Ethics Committee of Institute Jules Bordet (Belgium, Reference number: B079201628399), Pharma-Ethics, an Independent Research Ethics Committee (South Africa, Reference number: 161115075), and Clinical Research Ethics Committee of the Hospital Clinic de Barcelona (Spain; Reference number: HCB\/2017\/0661). Informed consent was obtained from each patient in writing before enrolment in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors give consent for the publication of the manuscript in the Journal, \u201cSupportive Care in Cancer\u201d.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BLR reports a research grant, personal fees, advisory boards, speaker engagements from Novartis and Sandoz, and personal fees and speaker engagements from Amgen South Africa, during the conduct of the study. MGM, CF, ZS, AAJ, HRK, FE, RAP, JG, LH, TS, TC, RA and JK have no relevant financial or non-financial interests to disclose. AK was a part of a study that received research grant from Sanofi. AK and NM are current or previous employees of Sandoz\/Hexal AG.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"628"}}